No, Nasrat already told us that he would PR the acceptance of the submission (which he estimates to be 45 to 60 days after they got the rest of the data) and not the sending of the last bit of data to the FDA. This means sending the extra data is not a material event, just like sending the data this spring was not. It is entirely reasonable that we will learn the data was submitted in the call tomorrow.
No, it would be filed under a subsequent event section. There is nothing there. If it was filed and they omitted the oxy filing they will have to amend the 10Q. A company simply can’t just leave info out like that from the financials.